Human Subject Protection Achievable Though Simpler Regs - OHRP's Koski
Executive Summary
Human research subject protections can be achieved though simpler regulations, HHS Office for Human Research Protections Director Greg Koski, MD/PhD, suggested.
You may also be interested in...
FDA Surveillance of Financial Conflict Of Interest Needs To Increase - Henney
Increased surveillance of financial conflict of interest is needed to guard against even a perception of bias by the public, FDA Commissioner Henney indicated during HHS' meeting on human subject protection and financial conflict of interest Aug. 15 at NIH.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials